Monte Rosa Therapeutics (GLUE) vs Odyssey Therapeutics (ODTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Monte Rosa Therapeutics is the larger company by market cap ($880.4 million vs $870.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GLUE | ODTX |
|---|---|---|
| Share price | $10.32 | $18.12 |
| Market cap | $880.43M | $870.82M |
| 1-day change | +1.47% | +0.22% |
| YTD return | -34.18% | — |
| 1-year return | +33.85% | — |
| 5-year return | -51.32% | — |
| EPS (TTM) | $-1.75 | $-7.55 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $25.77 | $29.05 |
| 52-week low | $8.53 | $15.10 |
| Distance from 52-week high | -59.95% | -37.62% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +171.32% | +97.30% |
| Average volume | 1.33M | 274.77K |
| Shares outstanding | 85.31M | 48.06M |
| Employees | 173 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Monte Rosa Therapeutics
GLUE stock →Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 173 employees
About Odyssey Therapeutics
ODTX stock →Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptorassociated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 100 employees
GLUE vs ODTX FAQ
Which is bigger, Monte Rosa Therapeutics or Odyssey Therapeutics?
Monte Rosa Therapeutics (GLUE) is larger, with a market capitalization of $880.43M compared with $870.82M for Odyssey Therapeutics (ODTX).
Are Monte Rosa Therapeutics and Odyssey Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.